Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company developing dropless therapies for glaucoma, corneal disorders, and retinal disease. Its products include Micro-Invasive Glaucoma Surgery devices to reduce intraocular pressure by restoring natural aqueous humor outflow, intracameral drug delivery technologies for sustained glaucoma medication, transdermal pharmaceuticals for glaucoma, dry eye, presbyopia, and other ocular diseases, and bio-erodible sustained release drug delivery implants to improve vision. The GKOS YTD return is shown above.
The YTD Return on the GKOS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether GKOS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GKOS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|